

WELCOME TO



This is an Education Platform

We Provide PDF Notes for Pharmacy Students

Web Site <http://www.fdspharmacy.in/>

You tube <https://www.youtube.com/c/FDSpharmacy>

Telegram <https://t.me/Fdspharmacy>

App <https://play.google.com/store/apps/details?id=com.FDSPharmacyMedia.FDSPharmacy>

E-mail fdspharmacyinfo@gmail.com

Bachelor of Pharmacy Industrial Pharmacy I

NOTES

- ✓ Unit 1
 - ✓ Unit 2
 - ✓ Unit 3
 - ✓ Unit 4
 - ✓ Unit 5
- All Unit
in
One PDF**

Visit our Website
WWW.fdspharmacy.in



Bachelor of Pharmacy Medicinal Chemistry II

NOTES

- ✓ Unit 1
 - ✓ Unit 2
 - ✓ Unit 3
 - ✓ Unit 4
 - ✓ Unit 5
- All Unit
in
One PDF**

Visit our Website
WWW.fdspharmacy.in



Bachelor of Pharmacy Pharmacognosy and Phytochemistry II

NOTES

- ✓ Unit 1
 - ✓ Unit 2
 - ✓ Unit 3
 - ✓ Unit 4
 - ✓ Unit 5
- All Unit
in
One PDF**

Visit our Website
WWW.fdspharmacy.in



Bachelor of Pharmacy Pharmaceutical Jurisprudence

NOTES

- ✓ Unit 1
 - ✓ Unit 2
 - ✓ Unit 3
 - ✓ Unit 4
 - ✓ Unit 5
- All Unit
in
One PDF**

Visit our Website
WWW.fdspharmacy.in



Bachelor of Pharmacy Pharmacology II

NOTES

- ✓ Unit 1
 - ✓ Unit 2
 - ✓ Unit 3
 - ✓ Unit 4
 - ✓ Unit 5
- All Unit
in
One PDF**

Visit our Website
WWW.fdspharmacy.in





D.Pharma B.Pharma

- 👉 PDF Notes
- 👉 Practical Manual
- 👉 Important Questions
- 👉 Assignment etc

 Download Now



www.fdpharmacy.in

MEDICINAL CHEMISTRY - II

UNIT 1

TOPIC :

- **H₂-antagonists : Cimetidine*, Famotidine, Ranitidin.**



H₂ Antagonists (H₂ Blockers)

H₂ antagonists, also called H₂ blockers, are a class of drugs that **reduce gastric acid secretion** by **blocking histamine H₂ receptors** on parietal cells of the stomach lining.

Histamine normally binds to H₂ receptors on **parietal cells**, stimulating gastric acid production. By blocking these receptors, H₂ antagonists decrease **basal and stimulated acid secretion**, helping manage acid-related disorders.

Mechanism of Action

1. H₂ antagonists act as **competitive antagonists** of histamine at H₂ receptors on parietal cells.
2. By binding to H₂ receptors, they **prevent histamine from activating the receptor**.
3. Without histamine stimulation, parietal cells **do not secrete gastric acid**, leading to a **reduction in overall acid production**.

Structure-Activity Relationship (SAR) of H₂ Antagonists

H₂ receptor antagonists were developed through **structural modifications of histamine** to find competitive inhibitors of H₂ receptors.

Key SAR points:

1. **Heterocyclic ring:**
 - Imidazole is classical, but **other heterocycles** (furan, thiophene, thiazole) can enhance potency and selectivity.
2. **Terminal nitrogen group:**
 - Should be **basic for optimal antagonistic activity**.
 - For some compounds, non-basic substitutions can reduce activity.
3. **Distance between ring and terminal nitrogen:**
 - Optimal **spacer of at least two atoms** is required for maximum receptor binding and antagonist effect.

Examples :


- Cimetidine
- Famotidine
- Ranitidine

Cimetidine

- Cimetidine is a **histamine H₂ receptor antagonist (H₂ blocker)**.
- It is used to **reduce gastric acid secretion** in conditions such as **peptic ulcer, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome**, and **stress ulcers**.
- It selectively blocks **H₂ receptors on gastric parietal cells** without affecting H₁-mediated allergic responses.
- It was the **first clinically successful H₂ antagonist**, discovered by **Sir James Black** in the 1970s.

Chemical Structure

- **IUPAC Name:** N-cyano-N-methyl-1-[2-[(5-methyl-1H-imidazol-4-yl)methyl]thio]ethyl]guanidine
- **Molecular Formula:** C₁₀H₁₅N₇S
- **Molecular Weight:** 252.34 g/mol
- **Chemical Structure**



Cimetidine

Mechanism of Action

- **H₂ Receptor Antagonism:**
 - Cimetidine selectively binds to **H₂ receptors on gastric parietal cells**.
 - Inhibits **histamine-mediated activation of adenylate cyclase**, reducing **cAMP formation** and **proton pump activity**.
 - Leads to **decreased secretion of gastric acid, pepsin, and intrinsic factor**.
- **No significant H₁ receptor activity:**
 - Does not affect allergic responses mediated by H₁ receptors.
- **Additional effects:**
 - Mild inhibition of **basal and nocturnal acid secretion**.

Synthesis of Cimetidine

1. Imidazole Preparation:

- Start with **4-methylimidazole** as the core ring system.

2. Side Chain Attachment:

- React 4-methylimidazole with **2-chloroethyl thioether** to introduce the thioether linkage.

3. Guanidine Formation:

- The terminal amine is converted to **N-cyano-N-methylguanidine**, forming the active Cimetidine molecule.

Uses

1. Peptic ulcer disease:

- Treatment and maintenance therapy for **duodenal and gastric ulcers**.

2. Gastroesophageal reflux disease (GERD):

- Reduces **acid reflux and heartburn**.

3. Zollinger-Ellison syndrome:

- Controls **gastric acid hypersecretion**.

4. Stress ulcers and prophylaxis:

- Reduces **gastric acidity in hospitalized patients**.

5. Other:


- Sometimes used off-label for **allergic conditions** due to weak **H₁ and H₂ combined effects**.

Famotidine

- Famotidine is a **histamine H₂ receptor antagonist (H₂ blocker)**.
- It is used to **reduce gastric acid secretion** in conditions such as **peptic ulcer disease, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and stress ulcers**.
- Famotidine is **more potent and longer-acting** than cimetidine and has **fewer drug interactions** because it does not inhibit cytochrome P450 enzymes significantly.
- It is available in **oral tablets, suspensions, and intravenous formulations**.

Chemical Structure

- **IUPAC Name:** 3-[[2-(diaminomethyleneamino)thiazol-4-yl]methylthio]-N-sulfamoylpropanimidamide
- **Molecular Formula:** C₈H₁₅N₇O₂S₃
- **Molecular Weight:** 337.43 g/mol
- **Chemical Structure**



Mechanism of Action

- **H₂ Receptor Antagonism:**
 - Famotidine selectively binds to **H₂ receptors on gastric parietal cells**.
 - Inhibits **histamine-induced activation of adenylate cyclase**, reducing **cAMP formation** and **proton pump activity**.
 - Results in **reduced gastric acid secretion, pepsin secretion, and basal/meal-stimulated acid output**.
- **CNS Effects:**
 - Minimal central effects; does not cause sedation.
- **Other Effects:**
 - Rapid onset and longer duration of action compared to cimetidine.
 - Minimal drug interactions due to **lack of significant CYP450 inhibition**.

Synthesis of Famotidine

1. Thiazole Formation:

- Prepare the **thiazole ring** with a **diaminomethylene substituent** at position 2.

2. Side Chain Introduction:

- Introduce the **thioether-linked 3-guanidino-propyl group** via nucleophilic substitution.

3. Sulfonamide Formation:

- Attach the **sulfonamide group** to the guanidine moiety, forming the **final Famotidine molecule**.

Uses

1. Peptic ulcer disease:

- Treatment and maintenance therapy for **duodenal and gastric ulcers**.

2. Gastroesophageal reflux disease (GERD):

- Reduces **acid reflux, heartburn, and esophagitis**.

3. Zollinger-Ellison syndrome:

- Controls **gastric acid hypersecretion**.

4. Stress ulcer prophylaxis:

- Reduces **gastric acidity in critically ill patients**.

5. Safe in elderly and patients with liver disease:


- Minimal hepatic metabolism, reducing the risk of drug interactions.

Ranitidine

- Ranitidine is a **histamine H₂ receptor antagonist (H₂ blocker)**.
- It was widely used to **reduce gastric acid secretion** in **peptic ulcer disease, gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and stress ulcers**.
- Ranitidine selectively blocks **H₂ receptors on gastric parietal cells**, thereby decreasing **acid and pepsin secretion**.
- Compared to **cimetidine**, ranitidine has **higher potency, fewer drug interactions**, and longer duration of action.
- **Note:** Many countries have withdrawn ranitidine due to **NDMA contamination**, a probable carcinogen.

Chemical Structure

- **IUPAC Name:** N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2-nitroethene-1,1-diamine
- **Molecular Formula:** C₁₃H₂₂N₄O₃S
- **Molecular Weight:** 314.42 g/mol
- **Chemical Structure**



Mechanism of Action

- **H₂ Receptor Antagonism:**
 - Ranitidine selectively binds to **H₂ receptors on gastric parietal cells**.
 - Inhibits **histamine-induced adenylate cyclase activation**, reducing **cAMP levels** and **proton pump activity**.
 - Results in **decreased secretion of gastric acid and pepsin**, reducing ulcer formation and acid reflux symptoms.
- **Other Effects:**
 - Reduces **basal and meal-stimulated gastric acid secretion**.
 - Minimal CNS effects and low sedation.

Synthesis of Ranitidine

1. Furan Derivative Preparation:

- 2-furaldehyde is reacted with **dimethylaminoethylthiol** to form the thioether intermediate.

2. Nitroethyl Substitution:

- The intermediate is reacted with **nitroethylenediamine** to introduce the **H₂ antagonistic nitroethyl moiety**.

3. Methylation:

- Terminal amine is methylated to yield **ranitidine base**, which is then purified.

Uses

1. Peptic ulcer disease:

- Treatment and maintenance therapy for **duodenal and gastric ulcers**.

2. Gastroesophageal reflux disease (GERD):

- Reduces **acid reflux, heartburn, and esophagitis**.

3. Zollinger-Ellison syndrome:

- Controls **gastric acid hypersecretion**.

4. Stress ulcer prophylaxis:

- Reduces **gastric acidity in critically ill patients**.

5. Adjunct therapy:

- Sometimes used with antibiotics in **H. pylori eradication regimens**.